All of our product candidates that are currently in clinical development and earlier stages of discovery and development emanate from discoveries made using our proprietary drug discovery platform. We believe that our expertise combined with our proprietary platform has allowed us to discover product candidates more efficiently than traditional approaches.
Our discovery approach is designed to introduce chemistry at an early stage in the drug discovery process and enable selection of the most attractive, drug-like chemistries for desired targets. A key to our discovery approach has been our set of proprietary assays that we developed for a large number of targets predominantly in the G-protein coupled receptor and nuclear receptor gene families. We believe that these gene families represent the most relevant and feasible targets for small molecule discovery focused on central nervous system indications. We have used our proprietary assays in conjunction with our proprietary receptor selection and simplification technology, a cell-based assay system which we refer to as R-SAT, to validate drug targets and to discover novel small molecules that are specific for these targets. We also have assembled a large and diverse proprietary chemical compound library of small organic molecules.back to top